Therapeutic strategies for congenital myasthenic syndromes

To date, more than 25 genes have been implicated in the etiology of the congenital myasthenic syndromes (CMS), and an ever-growing phenotypic landscape is now encountered in the CMS clinic. Unlike the autoimmune form of myasthenia, there is no role for immunomodulatory agents in the treatment of CMS...

Description complète

Détails bibliographiques
Auteurs principaux: Lee, M, Beeson, D, Palace, J
Format: Journal article
Langue:English
Publié: Wiley 2018

Documents similaires